EUVIMEDEUVIMED entdecken
Multizentrische Studie

Ibrutinib Dose Adjustment Does Not Impair Treatment Outcome in Mantle Cell Lymphoma: An Italian Real‐Life Multicenter Experience. Results From the REDOT_MCL Study

Francesca Maria Quaglia iD, Lara Mannelli, Luca Pagliaro, Greta Scapinello, Luana Schiattone, Mirko Farina, Mattia Novo, Piera Angelillo, Roberta Sciarra, Elena Maiolo, Elisa Lucchini, Valeria Tomarchio und 5 weitere

Hematological Oncology · 2026-05 · 44 (3)

DOI: 10.1002/hon.70190 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Hematological Oncology, online erschienen am 02.04.2026. Verfasst von Francesca Maria Quaglia und 16 weiteren Autor:innen. Beteiligte Einrichtung: UOC di Ematologia, DAI Medico Generale, AOUI Verona, Verona, Italy. Hauptthemen laut MEDLINE: Lymphoma, Mantle-Cell, Piperidines, Adenine, Protein Kinase Inhibitors. Die Arbeit nennt 37 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BTK inhibitors (BTKi) have reshaped the therapeutic algorithm of lymphoproliferative diseases, but class‐specific adverse events (AEs) have emerged. Dose adjustment (DA) is often attempted to mitigate AEs, particularly with ibrutinib, the first BTKi approved for relapsed/refractory (R/R) mantle cell lymphoma (MCL) patients. We described ibrutinib DA in 226 consecutive R/R MCL who started ibrutinib between 2016 and 2023. We assessed DA rate and calculated single patient's relative ibrutinib dose as a percentage of the expected full dose during the entire treatment period, grouping patients into 4 dose levels (DL1a 95%–100%, DL1b 75%–94%, DL2a 50%–74%, DL2b < 50%). We evaluated changes in response, progression free survival (PFS), overall survival (OS) and time to next treatment (TTNT) between groups. Thirty‐four percent of patients started ibrutinib at reduced dose, mainly due to age/comorbidities. Overall, 44% of patients reduced ibrutinib dose, mostly due to AEs. Thirty‐five percent of patients interrupted treatment, predominantly for AEs, and 65% of patients discontinued ibrutinib, most often due to progressive disease (70%). No statistically significant differences in response rates/PFS/OS were observed across DLs. Interestingly, patients on the lowest dose tended to remain on treatment longer. This is the first real‐life report evaluating ibrutinib DA in MCL. We showed that DA is common, particularly in older comorbid patients, and doesn't compromise efficacy, making it a feasible strategy for managing ibrutinib‐related toxicities.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphoma, Mantle-CellPiperidinesAdenineProtein Kinase InhibitorsHumansFemaleMaleAgedItalyAged, 80 and overTreatment OutcomeAgammaglobulinaemia Tyrosine Kinase

Stichwörter der Autor:innen

AEsMCLdose adjustmentibrutinib

Substanzen

ibrutinibPiperidinesAdenineProtein Kinase InhibitorsAgammaglobulinaemia Tyrosine Kinase

Autor:innen und Institutionen

  • UOC di Ematologia, DAI Medico Generale, AOUI Verona, Verona, Italy.
  • Unit of Oncohematology, Department of Oncology, Azienda USL Toscana Centro, Prato, Italy.
  • Dipartimento di Medicina e Chirurgia, Università Degli Studi di Parma, Parma, Italy.
  • Division of Hematology, Ospedale Universitario di Padova, Padova, Italy.
  • Unità di Ematologia, Ospedale Civile S. Spirito, Pescara, Italy.
  • Unit of Blood Diseases and Bone Marrow Transplantation, Cell Therapies and Hematology Research Program, University of Brescia, ASST Spedali Civili di Brescia, Brescia, Italy.

ORCID-Profile: Francesca Maria Quaglia, Francesco Zaja

Zitieren

APA

Quaglia, F. M., Mannelli, L., Pagliaro, L., Scapinello, G., Schiattone, L., Farina, M., Novo, M., Angelillo, P., Sciarra, R., Maiolo, E., Lucchini, E., Tomarchio, V., Ghiggi, C., Pelliccia, S., Marangon, M., Marcheselli, L., & Zaja, F. (2026). Ibrutinib Dose Adjustment Does Not Impair Treatment Outcome in Mantle Cell Lymphoma: An Italian Real‐Life Multicenter Experience. Results From the REDOT_MCL Study. Hematological Oncology, 44(3). https://doi.org/10.1002/hon.70190

Vancouver

Quaglia FM, Mannelli L, Pagliaro L, Scapinello G, Schiattone L, Farina M, et al. Ibrutinib Dose Adjustment Does Not Impair Treatment Outcome in Mantle Cell Lymphoma: An Italian Real‐Life Multicenter Experience. Results From the REDOT_MCL Study. Hematological Oncology. 2026;44(3). doi:10.1002/hon.70190

BibTeX
@article{Quaglia2026,
  author = {Quaglia, Francesca Maria and Mannelli, Lara and Pagliaro, Luca and Scapinello, Greta and Schiattone, Luana and Farina, Mirko and Novo, Mattia and Angelillo, Piera and Sciarra, Roberta and Maiolo, Elena and Lucchini, Elisa and Tomarchio, Valeria and Ghiggi, Chiara and Pelliccia, Sabrina and Marangon, Miriam and Marcheselli, Luigi and Zaja, Francesco},
  title = {Ibrutinib Dose Adjustment Does Not Impair Treatment Outcome in Mantle Cell Lymphoma: An Italian Real‐Life Multicenter Experience. Results From the REDOT_MCL Study},
  journal = {Hematological Oncology},
  year = {2026},
  volume = {44},
  number = {3},
  doi = {10.1002/hon.70190}
}
Kostenlos starten →